imdevimab

BIOLOGICAL2 trials

Sponsors

Sohail Rao, Regeneron Pharmaceuticals

Conditions

Covid19SARS-CoV-2

Phase 1

COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease

TerminatedNCT05081388

Regeneron PharmaceuticalsSARS-CoV-2

Start: 2021-11-08End: 2022-06-30Updated: 2025-10-28

Phase 2

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

Sohail RaoCovid19

Start: 2020-11-20End: 2023-01-31Target: 1000Updated: 2022-03-29